Conflicts and Disclosures

- I have no conflicts of interest to disclose
Ms Rb / 49
no comorbid

<table>
<thead>
<tr>
<th>Diagnosis 2013</th>
<th>Dec 2015: Disease progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013 (aged 44)</td>
<td>MMG Right retroareolar lesion BIRADS 4</td>
</tr>
<tr>
<td>Right breast IDC cT2N1M0</td>
<td>Biopsy Invasive ca, ER + PR- HER2 -</td>
</tr>
<tr>
<td>Aug 2013 CT TAP</td>
<td>Jan 2016 CT TAP</td>
</tr>
<tr>
<td>Right breast mass 3.6x4.7 cm</td>
<td>Right breast mass 2.8 x 2.8 x 3.6 cm</td>
</tr>
<tr>
<td>Cystic adnexal mass 2.5x2.7 cm, bulky cervix</td>
<td>Adnexal mass 4.5 x 3.9 x 4.7 cm</td>
</tr>
<tr>
<td><strong>Neoadjuvant FEC x 6</strong></td>
<td>Mediasternal LN, bone metastasis</td>
</tr>
<tr>
<td>Feb 2014 Wide local excision + AC</td>
<td>Biopsy adnexal mass: metastatic carcinoma consistent with breast primary</td>
</tr>
<tr>
<td>ypT2N0M0 ER+ PR- HER2-</td>
<td><strong>June 2016 Docetaxel x 6</strong></td>
</tr>
<tr>
<td>April 2014 Adjuvant RT to right breast</td>
<td>July 2016 CT TAP</td>
</tr>
<tr>
<td>40Gy/15F/3weeks + boost 16Gy/8F</td>
<td>Reduced breast and adnexal mass lesion</td>
</tr>
<tr>
<td><strong>Apr 2014- Dec 2015 Tamoxifen</strong></td>
<td>Resolved mediasternal LN, stable bone mets</td>
</tr>
<tr>
<td></td>
<td>RT to pelvis 16Gy/4F/4days (AIM)</td>
</tr>
<tr>
<td></td>
<td><strong>Sept 2016 Letrozole</strong></td>
</tr>
</tbody>
</table>
Ms Rb / 49
no comorbid

Dec 2016
Suprapubic mass 15x15 cm

TAHBSO
HPE : metastatic carcinoma, consistent with breast primary
tolerating Letrozole well
ECOG 1

April 2017
Right breast mass 9x9cm
Left breast mass 4x4cm
Offered chemotherapy, defaulted

June 2017 Gemcitabine
Clinically disease progress at C2D1
Right breast 20x20cm , ulceration, fungating mass
Left breast mass 10x10cm

July 2017 CMF regime
Failed at Cycle 4
Right breast 20x20cm fungating mass, skin nodules
Left breast 12x12cm, skin nodules

Sept 2017 Vinorelbine x 6
Jan 2018 Exemestane
ECOG 1

March 2018 Capecitabine
Cycle 1 Capecitabine
1 episode of bleeding tumor (minimal) – supportive treatment
Cycle 2 Capecitabine
ECOG 2
Deteriorating, defaulted treatment
Diagnosed in 2013
- Disease progression within 2 years of first line hormonal therapy

2013-2018
- Failed 5th lines of chemotherapy
- Failed 3rd line of hormonal therapy
- ECOG 2

? taxane based (neoadjuvant)
? + ovarian suppression

? CDK 4/6 inhibitor after many lines of treatment

NEXT step?

Thank you
rizma@ummc.edu.my